ASCRS 2024: Real-world results with an enhanced monovision toric lens

News
Video

Josefina Botta, MD, MSc, discusses her real-world experiences with the RayOne EMV toric lens

Well, hello, everyone, I'm Dr Josefina Botta from Buenos Aires, Argentina, and today we're here in Boston, attending the ASCRS meeting. This year, it's been phenomenal. We had such a good turnout. I actually presented my real results using the RayOne EMV toric lens.

It's been really challenging to be able to present it here, for the American audience, not because they don't get with the message we're trying to deliver, but only because they don't have the lens yet. So I've been trying to introduce the lens for them. It's a real, really good lens; it's monofocal plus, that's a way we actually picture it to everyone. So we've been able to show results, show how stable the lens is in the bag. It doesn't rotate, the calculation is pretty accurate. And you're going to be able to give your patients real good distance vision, intermediate vision. And sometimes, when you play a bit with micromonovision or minimonovision, you're going to be able to deliver some functional near vision. So of course, we're not talking about a trifocal lens, but still very functional, very practical, from our point of view.

And also in correlation with what I'm just explaining, we will be working with the RayPRO platform, which is a digital platform that it's been created by Rayner, both for desktops and [as an app]. The only thing you need to do is to introduce your patient's email address, the type of lens you placed, it doesn't have to be a Rayner lens of course, because we're trying to be collaborative and work around with everyone. And we're very focused on their responses to the Cat-PROM5 questionnaire where they would answer what their experiences so we are very focused into the patient's experience. And we were able to actually come up with really good conclusions that we weren't expecting. Their number one complaint, the number one reason why they wouldn't be happy with our surgeries is because of dysphotopsias, and not much in relation to the use of glasses after surgeries.

We're going to be presenting these results in the upcoming ESCRS this year in Barcelona. So we hope to find you there and if there's any questions you may be able to contact myself or a member of our team. Thank you very much.

Newsletter

Join ophthalmologists across Europe—sign up for exclusive updates and innovations in surgical techniques and clinical care.

Recent Videos
At the Retina World Congress, Siegfried Priglinger, MD, speaks about ensuring the best outcomes for preschool-aged patients
At the 2025 ASCRS meeting, Robert Ang, MD said small aperture IOLs can benefit all patients, especially those with complex corneas or who have undergone previous corneal refractive surgery
Viha Vig, MBChB graduate student at the University of Auckland, New Zealand, discusses her poster presentation on the relationship between mitochondiral disease, Alzheimer disease, and other types of dementia.
Alfredo Sadun, MD, PhD, chief of Ophthalmology at the Doheny Eye Institute, University of California Los Angeles, shared exciting new research with the Eye Care Network during the Association for Research in Vision and Ophthalmology (ARVO) meeting on the subject of Leber hereditary optic neuropathy (LHON).
At this year's Association for Research in Vision and Ophthalmology (ARVO) meeting in Salt Lake City, Utah, Nitish Mehta, MD, shared highlights from his research documenting real-world results of aflibercept 8 mg for patients with diabetic macular oedema.
ARVO 2025: Anat Loewenstein, MD, shares data from herself and her colleagues on meeting needs of patients with diabetic retinopathy
At the American Society of Cataract and Refractive Surgeons annual meeting, Sheng Lim, MD, FRCOphth discusses the benefit of endoscopic cyclophotocoagulation for patients with primary open angle glaucoma and cataracts in the CONCEPT study
A photo of Seville, Spain, with the Congress on Controversies in Ophthalmology logo superimposed on it. Image credit: ©francovolpato – stock.adobe.com; logo courtesy COPHy
Anat Loewenstein, MD, Professor and Director, Department of Ophthalmology, Tel Aviv Medical Center, discusses the Congress on Controversies in Ophthalmology (COPHy)
Anat Loewenstein, MD, speaks about the 22nd Annual Angiogenesis, Exudation, and Degeneration Meeting in February 2025 and shares her global forecast for AI-driven home OCT
© 2025 MJH Life Sciences

All rights reserved.